Cargando…
Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
PURPOSE: PEGylated liposomes are important drug carriers that can passively target tumor by enhanced permeability and retention (EPR) effect in neoplasm lesions. This study demonstrated that tumor burden determines the tumor uptake, and also the tumor response, in cancer treatment with PEGylated lip...
Autores principales: | Lin, Yi-Yu, Kao, Hao-Wen, Li, Jia-Je, Hwang, Jeng-Jong, Tseng, Yun-Long, Lin, Wuu-Jyh, Lin, Ming-Hsien, Ting, Gann, Wang, Hsin-Ell |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651236/ https://www.ncbi.nlm.nih.gov/pubmed/23675454 http://dx.doi.org/10.1371/journal.pone.0063078 |
Ejemplares similares
-
Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes
por: Hsieh, Yuan-Chin, et al.
Publicado: (2018) -
PEGylated liposome-encapsulated rhenium-188 radiopharmaceutical inhibits proliferation and epithelial–mesenchymal transition of human head and neck cancer cells in vivo with repeated therapy
por: Chang, Chun-Yuan, et al.
Publicado: (2018) -
A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015) -
Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles
por: Hsieh, Yuan-Chin, et al.
Publicado: (2016) -
PEGylated liposomes: immunological responses
por: Mohamed, Marwa, et al.
Publicado: (2019)